JPS57105423A - Chloroethylureidopropylpolysilsesquioxane - Google Patents

Chloroethylureidopropylpolysilsesquioxane

Info

Publication number
JPS57105423A
JPS57105423A JP18140880A JP18140880A JPS57105423A JP S57105423 A JPS57105423 A JP S57105423A JP 18140880 A JP18140880 A JP 18140880A JP 18140880 A JP18140880 A JP 18140880A JP S57105423 A JPS57105423 A JP S57105423A
Authority
JP
Japan
Prior art keywords
chloroethylureido
propyltriethoxysilane
structural units
expressed
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP18140880A
Other languages
Japanese (ja)
Other versions
JPS6147165B2 (en
Inventor
Shozo Kato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tokuyama Corp
Original Assignee
Tokuyama Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokuyama Corp filed Critical Tokuyama Corp
Priority to JP18140880A priority Critical patent/JPS57105423A/en
Publication of JPS57105423A publication Critical patent/JPS57105423A/en
Publication of JPS6147165B2 publication Critical patent/JPS6147165B2/ja
Granted legal-status Critical Current

Links

Abstract

PURPOSE: The titled compound, consisting of specific structural units, obtained by hydrolyzing 3-(β-chloroethylureido)propyltriethoxysilane, etc., relatively stable to acids and alkalis, and suitable for a carcinostatic agent.
CONSTITUTION: 3-( β-chloroethylureido )propyltriethoxysilane expressed by formulaIis hydrolyzed and condensed preferably at 0W80°C for 1W60hr to give the aimed compound consisting of structural units expressed by formula II. The resultant compound has remarkably improved physiological activity compared with other polysilsesquioxanes, and exhibits improved effects particularly on the carcinostatic activity with relatively mild toxicity and suitably usable for the prevention, remedy and treatment of various cancers. The form of use is any one of the oral, parenteral or local administration, and the effective dose thereof is 50W0.02mg/kg/day. The active constituent concentration is preferably 1W60wt%.
COPYRIGHT: (C)1982,JPO&Japio
JP18140880A 1980-12-23 1980-12-23 Chloroethylureidopropylpolysilsesquioxane Granted JPS57105423A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP18140880A JPS57105423A (en) 1980-12-23 1980-12-23 Chloroethylureidopropylpolysilsesquioxane

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP18140880A JPS57105423A (en) 1980-12-23 1980-12-23 Chloroethylureidopropylpolysilsesquioxane

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP272784A Division JPS59144792A (en) 1984-01-12 1984-01-12 3-(beta-chloroethylureide)propyl triethoxy silane

Publications (2)

Publication Number Publication Date
JPS57105423A true JPS57105423A (en) 1982-06-30
JPS6147165B2 JPS6147165B2 (en) 1986-10-17

Family

ID=16100231

Family Applications (1)

Application Number Title Priority Date Filing Date
JP18140880A Granted JPS57105423A (en) 1980-12-23 1980-12-23 Chloroethylureidopropylpolysilsesquioxane

Country Status (1)

Country Link
JP (1) JPS57105423A (en)

Also Published As

Publication number Publication date
JPS6147165B2 (en) 1986-10-17

Similar Documents

Publication Publication Date Title
JPS53113008A (en) Constant rate releasing preparation
JPS5551020A (en) Remedy for rheumatism
FI955837A0 (en) Process for the preparation of an orally administrable solid dosage form containing diclofenac
JPS57109721A (en) Carcinostatic agent
JPS57105423A (en) Chloroethylureidopropylpolysilsesquioxane
JPS55122715A (en) Antidiabetic agent
JPS57114512A (en) Antidia beticagent comprising (3-dimethyl-carbamoxy- phenyl)trimethyl ammonium derivative
JPS56115715A (en) Physiologically active agent containing (3- dimethylcarbam-oxyphenyl) trimethyl ammonium derivative
JPS5634626A (en) Anti-inflammatory
JPS5742620A (en) Novel antiulcer agent
JPS5551018A (en) Carcinostatic agent
JPS5639019A (en) Antiviral agent
JPS5498339A (en) Carcinostatic agent
JPS57114519A (en) Antiarteriosclerotic agent
JPS5675432A (en) Antitumor agent containing ethyl piperidylacetylaminobenzoate
JPS53130496A (en) Preparation of polysaccharides
JPS5634624A (en) Central nervous system depressant
JPS57128625A (en) Carcinostatic
JPS57114518A (en) Hypotensive agent
JPS57114513A (en) Drug against arterioscleriosis comprising (3-dimethylca- rbamoxyphenyl)trimethyl ammonium derivative
JPS5634625A (en) Antitumorigenic agent
JPS55122719A (en) Medicine composition having antipyretic, analgesic, and anti-inflammatory action
JPS5675427A (en) Antiarteriosclerotic agent containing procainamide hydrochloride
JPS5759809A (en) Cardiotonic agent
JPS57114514A (en) Antiphlogistic comprising (3-dimethylcarbamoxyphenyl) trimethyl ammonium derivative